| Nov 13 |
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
|
| Nov 11 |
ONVO Releases Encouraging Quarterly Results
|
| Oct 25 |
Organovo Holdings files to sell common stock, warrants
|
| Aug 6 |
ONVO Announces Earnings and Notes Potential for Acquisition
|
| Jul 18 |
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July
|
| Jul 16 |
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
|
| Jun 4 |
ONVO Increases Cash and Improves Prospects
|
| May 21 |
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
|
